Business Wire

Sotera Health’s Nelson Labs Announces Acquisition of New Jersey-Based Gibraltar Laboratories

Del

Sotera Health, the world’s leading, fully integrated protector of global health, announced today that it has acquired New Jersey-based Gibraltar Laboratories. This acquisition expands the U.S.-based analytical testing capabilities of Sotera Health’s Nelson Labs business. Gibraltar Laboratories is a leading outsourced provider of microbiology and analytical chemistry testing for pharmaceutical and medical device manufacturers. Terms of the deal were not disclosed.

Headquartered in Fairfield, New Jersey, Gibraltar Laboratories has an outstanding reputation for customer service, technical expertise and quality performance. Gibraltar is known for USP compendial microbiology, sterility assurance and analytical chemistry testing. The company, owned and operated by the Prince family since 1970, runs two laboratories in the New Jersey tri-state area.

“Gibraltar Laboratories is a well-respected laboratory known for its strong customer relationships with U.S.-based pharmaceutical manufacturers,” said Michael B. Petras Jr., CEO of Sotera Health. “In addition to its testing expertise, Gibraltar’s facilities are located in the Northeast pharmaceutical corridor, home to many of the top pharmaceutical manufacturers in the United States. This acquisition will expand our presence in this important region and further strengthen our testing capabilities for the pharmaceutical industry. We welcome Gibraltar’s strong management and expert staff as they join our mission of Safeguarding Global HealthTM.”

“Through the commitment of three generations of the Prince family, as well as our experienced staff of microbiology and chemistry professionals, we have earned a reputation as a reliable, responsive and highly professional partner for our customers, and we know we have found the same in Sotera Health,” said Dr. Daniel L. Prince, President of Gibraltar Laboratories. “My goal is for Gibraltar to continue to build on its long-standing reputation of excellence and continue to expand its offerings. We accomplish this by becoming part of Sotera Health, a global company whose breadth of services and expansive reach provide extraordinary value to the industries we are proud to serve.”

“Gibraltar’s offerings and the strategic location of its facilities will be a great benefit to our mutual customers, who value working with a trusted partner that can consistently deliver quality, service and expertise,” said Jeff Nelson, President of Nelson Labs. “The Gibraltar team is known for these values and also has an excellent reputation for designing specialized studies that help manufacturers prove the safety, efficacy and regulatory compliance of their products. I am also personally excited to be working directly with Dr. Daniel Prince, who I consider a leading thinker in our field.”

Gibraltar will complement Sotera Health’s Nelson Labs business. Gibraltar’s expertise in pharmaceutical products and analytical testing capabilities will enhance Nelson Labs’ existing strengths in medical device microbiology and expert advisory services. Gibraltar’s facilities are FDA registered and ISO 17025 accredited and have the distinction of being accredited for both the microbiological and chemical fields. The acquisition of Gibraltar Laboratories does not include Prince Sterilization Services, LLC. However, both companies are excited that Gibraltar will continue to maintain a partnership with Prince Sterilization Services to provide the testing needed to certify their products.

About Sotera Health: Sotera Health LLC, along with its business entities, is the world’s leading, fully integrated protector of global health. With over 500 years of combined scientific expertise, the company ensures the safety of healthcare by providing mission-critical services to the medical device, pharmaceutical, tissue and food industries. Sotera Health operates 63 facilities in 13 countries. The company has over 2,600 employees globally and touches the lives of more than 180 million people around the world each year. Sotera Health serves more than 5,000 customers worldwide, including 75 of the top 100 medical device manufacturers.

Sotera Health goes to market through its three best-in-class companies – Nelson Labs™, Nordion® and Sterigenics® – with the mission of ensuring the safety of health care each and every day. Nelson Labs offers microbiological and analytical testing and expert advisory services to assist customers in developing and maintaining sterilization solutions in medical devices, tissue/implantable products, and the pharmaceutical and biologics fields. Nordion is the world’s largest provider of Cobalt-60 used in the gamma sterilization process, and Sterigenics provides comprehensive contract sterilization and ionization solutions for the medical device, pharmaceutical, food safety and high-performance materials industries.

Sotera Health LLC is owned by private equity firms Warburg Pincus and GTCR. Learn more about Sotera Health at soterahealth.com, about Nelson Labs at nelsonlabs.com, about Nordion at nordion.com and about Sterigenics at sterigenics.com.

About Nelson Laboratories: Nelson Laboratories, LLC is the industry-leading provider of global lab testing and expert advisory services. Nelson Labs performs over 400 rigorous microbiological and analytical laboratory tests, including a best-in-class extractables and leachables testing platform, for the medical device, pharmaceutical and tissue industries. The company is regarded as a best-in-class partner with a strong track record of collaborating with customers to solve complex issues. With 11 global laboratory locations in 8 countries, Nelson Labs is committed to Safeguarding Global HealthTM with every test they complete.

About Gibraltar Laboratories: With an outstanding reputation for customer service, quality research, quality control and testing in stem cells, bacteriology, mycology, virology, chemistry, cleaning validations and in vitro toxicology, Gibraltar Laboratories has set the Gold Standard for contract laboratories. Gibraltar Laboratories proudly serves the pharmaceutical, medical device, orthopedic, tissue bank, biopharmaceutical, chemical, and cosmetic industries. The company operates two laboratories and is based in Fairfield, New Jersey. To learn more, visit www.gibraltarlabsinc.com.

Contact information

Dix & Eaton for SOTERA HEALTH:
Angela Martin, 216-241-2148
amartin@dix-eaton.com
or
GIBRALTAR LABORATORIES:
Danina Rinaldi, 973-227-6882 ext. 529
Technical Services Manager
drinaldi@gibraltarlabsinc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies24.6.2019 23:00:00 CESTPressemelding

Gilead Sciences, Inc. (NASDAQ: GILD) and Carna Biosciences Inc. (JASDAQ: 4572) today announced that the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005487/en/ Under the terms of the license agreement, Gilead will license from Carna worldwide rights to develop and commercialize inhibitors against an undisclosed immuno-oncology target. In connection with this agreement, Carna will receive an upfront payment of $20 million and is eligible to receive up to an additional $450 million in potential milestone payments upon achievement of certain development and commercial milestones. Carna will also receive royalties on future net sales. "We are delighted to partner with Gilead on our immuno-oncology pipeline targ

iMarketKorea Switches to Rimini Street Support for its SAP Application24.6.2019 22:00:00 CESTPressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that iMarketKorea, the country’s leading B2B e-commerce company, has switched from SAP to Rimini Street support for their SAP ECC system. By switching to Rimini Street, iMarketKorea was able to reduce its annual support fees by 50 percent and are now able to run their current stable ERP system for a minimum of 15 years from the time they moved to Rimini Street, without being forced to upgrade by SAP’s published 2025 end of mainstream maintenance window for ECC 6. Because of the premium level of ERP support the company now receives, iMarketKorea’s IT staff have been relieved of the day to day back office system maintenance, which is now entirely handled by Rimini Street, and are able to focus on and support more strategic projects within their company. This press release

IFF and ISIPCA Celebrate First Master of Scent Design Graduating Class24.6.2019 20:15:00 CESTPressemelding

Regulatory News: IFF (NYSE:IFF) (Euronext Paris:IFF) (TASE:IFF), a leading innovator of taste, scent, and nutrition & ingredients, and ISIPCA, a prestigious higher education institution in the field of perfume, cosmetics, and flavoring, today celebrate the first Master of Scent Design and Creation graduating class of their collaborative program, established in 2016. “This is an historic day with many reasons to celebrate,” said Nicolas Mirzayantz, Scent Division CEO, IFF. “This is the first Masters of Scent Design & Creation graduating class from the first collaboration of its kind in the industry. We are thrilled at the sheer quality and passion of the well-trained and talented class, who are poised and ready to contribute to the world of fragrance. And we are happy to see such a diverse and inclusive group, reflecting the consumers for whom they will create.” The three-year program, based in Versailles, France, offers students a strong foundation in the art of perfumery, including an

3,900-Acre Wyoming “Holy Cow Ranch” Neighboring Bighorn National Forest to Auction via Concierge Auctions24.6.2019 19:58:00 CESTPressemelding

A 3,900-acre property located halfway between Yellowstone Park and Mount Rushmore in Sheridan, Wyoming – affectionately known as Holy Cow Ranch – will auction next month via leading global firm Concierge Auctions. The property features five structures including a guest lodge and owner’s residence, a pool with pool house, tennis courts, and miles of Bighorn National Forest frontage. Previously listed for $23.5 million, 43 Rapid Creek Road will auction Without Reserve in cooperation with Bruce Garber, Joe Steger, and Roger St Clair of Century 21 BHJ Realty, Inc. Bidding, which will be held via Concierge Auctions’ online marketplace, will open July 23rd and close July 26th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190624005652/en/ Holy Cow Ranch – Sheridan, WY (Photo: Business Wire) “The auction of Holy Cow Ranch presents the opportunity to own a truly impressive range of some of North America’s most beautiful landscapes,

 Avioq Announces CE Mark and European Launch of VioOne HIV Profile Supplemental Assay24.6.2019 15:11:00 CESTPressemelding

Avioq, Inc. has received CE Marking (Conformité Européenne) and has begun marketing their VioOne™ HIV Profile™ Supplemental Assay in the European Union and other CE Mark countries. The product has also been submitted for FDA approval. “We are pleased to provide the CE Mark HIV Profile™ assay to countries outside the U.S.,” said Chamroen Chetty, CEO of Avioq. Dr. Chetty continues, “We are also looking for distribution partners to expand the global availability.” The HIV Profile™ is an enzyme-linked immunosorbent assay (ELISA) for confirmation and differentiation of individual antibodies directed to various gene products of HIV-1 (Group M & Group O) and HIV-2 in human serum or plasma that were repeatedly reactive in diagnostic screening procedures. Results can also be used to distinguish recent from longstanding HIV-1 infection for HIV-1 incidence estimation. About Confirmatory Testing In 2014, the CDC released a new algorithm for HIV testing. The second step of the algorithm includes a

Global Launch of S BLOCK, Kicked Off in Singapore on June 22nd24.6.2019 12:29:00 CESTPressemelding

The globally renowned 2019 WBF Singapore Technology Conference was held in Marina Bay Sands Hotel on June 22nd, 2019. S BLOCK, the conference co-host, unveiled itself and announce its mission to “Unleash your digital assets” for the first time. The conference brought together numerous industry elites and blockchain enthusiasts from all around the world, including more than 500 industry veterans from over 30 countries, such as Switzerland, Germany, France, Russia, Japan, Korea, Brazil, Australia, Argentina and Canada. Insiders shared profound global industry insights. This conference draws great attention from across the global blockchain industry. S BLOCK Kicked Off in Singapore In the morning of June 22nd, Ivan - President of S BLOCK Global Foundation, was invited to deliver a keynote speech, “Next Generation Digital Currency Wallet”. At this conference, S BLOCK was officially launched in more than 30 countries around the world, and opened up the way to a global future without borders